{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:13:45Z","timestamp":1772237625324,"version":"3.50.1"},"reference-count":72,"publisher":"Impact Journals, LLC","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,4]]},"DOI":"10.18632\/oncotarget.16689","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T05:06:35Z","timestamp":1490850395000},"page":"44976-44993","source":"Crossref","is-referenced-by-count":10,"title":["Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis"],"prefix":"10.18632","volume":"8","author":[{"given":"De-Dong","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Lin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fifth Hospital of WuHan, WuHan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Fa","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Fa","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Ming","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Oncology, RenMin Hospital of WuHan University, WuHan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"key":"1","first-page":"332","article-title":"Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region","volume":"10","author":"Yuen","year":"2016","journal-title":"Gut Liver"},{"key":"2","first-page":"5234969","article-title":"Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis","volume":"2016","author":"Qian","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"3","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.3748\/wjg.v12.i43.6955","article-title":"Efficacy and safety of thalidomide in patients with hepatocellular carcinoma","volume":"12","author":"Liu","year":"2006","journal-title":"World J Gastroenterol"},{"key":"4","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.4254\/wjh.v7.i16.2029","article-title":"Optimal combination of antiangiogenic therapy for hepatocellular carcinoma","volume":"7","author":"Ch\u2019ang","year":"2015","journal-title":"World J Hepatol"},{"key":"5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13027-016-0082-9","article-title":"Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment","volume":"11","author":"Izzo","year":"2016","journal-title":"Infect Agent Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4254\/wjh.v8.i14.607","article-title":"Liver resection for intermediate hepatocellular carcinoma","volume":"8","author":"Xu","year":"2016","journal-title":"World J Hepatol"},{"key":"7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/1751-2980.12380","article-title":"Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis","volume":"17","author":"Ye","year":"2016","journal-title":"J Dig Dis"},{"key":"8","first-page":"710","article-title":"Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs","volume":"62","author":"Li","year":"2015","journal-title":"Surgical Resection (SR) on Survival Outcome of Early Hepatocellular Carcinoma: A Meta-Analysis. Hepatogastroenterology"},{"key":"9","doi-asserted-by":"crossref","first-page":"e100305","DOI":"10.1371\/journal.pone.0100305","article-title":"Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis","volume":"9","author":"Bie","year":"2014","journal-title":"PLoS One"},{"key":"10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000367757","article-title":"Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON Registry","volume":"5","author":"Cohn","year":"2016","journal-title":"Liver Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.3748\/wjg.v21.i19.6018","article-title":"Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients","volume":"21","author":"Gadaleta","year":"2015","journal-title":"World J Gastroenterol"},{"key":"12","doi-asserted-by":"publisher","first-page":"83806","DOI":"10.18632\/oncotarget.11514","article-title":"Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma","volume":"7","author":"Shen","year":"2016","journal-title":"Oncotarget"},{"key":"13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3748\/wjg.v20.i2.486","article-title":"Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment","volume":"20","author":"Gadaleta","year":"2014","journal-title":"World J Gastroenterol"},{"key":"14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000445730","article-title":"Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: standards and Developments","volume":"32","author":"Schnitzbauer","year":"2016","journal-title":"Visc Med"},{"key":"15","first-page":"175","article-title":"The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma","volume":"52","author":"Skomra","year":"2005","journal-title":"Neoplasma"},{"key":"16","doi-asserted-by":"crossref","first-page":"27280","DOI":"10.1038\/srep27280","article-title":"HIF-1\u03b1 and HIF-2\u03b1 induced angiogenesis in gastrointestinal vascular malformation and reversed by thalidomide","volume":"6","author":"Ge","year":"2016","journal-title":"Sci Rep"},{"key":"17","doi-asserted-by":"crossref","first-page":"11081","DOI":"10.1007\/s13277-016-4963-8","article-title":"Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials","volume":"37","author":"Shi","year":"2016","journal-title":"Tumour Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4103\/0366-6999.174497","article-title":"Thalidomide-based Regimens for Elderly and\/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis","volume":"129","author":"Wei","year":"2016","journal-title":"Chin Med J (Engl)"},{"key":"19","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2014-0283","article-title":"Chronic thalidomide and chemoembolization for hepatocellular carcinoma","volume":"19","author":"Muggia","year":"2014","journal-title":"Oncologist"},{"key":"20","first-page":"39","article-title":"The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis","volume":"18","author":"Chen","year":"2014","journal-title":"Contemp Oncol (Pozn)"},{"key":"21","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3892\/ijo.2015.3155","article-title":"Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer","volume":"47","author":"Lai","year":"2015","journal-title":"Int J Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/02656736.2015.1099168","article-title":"Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma","volume":"32","author":"Huang","year":"2016","journal-title":"Int J Hyperthermia"},{"key":"23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s12072-014-9557-1","article-title":"Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide","volume":"9","author":"Liu","year":"2015","journal-title":"Hepatol Int"},{"key":"24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1476-511X-12-175","article-title":"Lipid droplet binding thalidomide analogs activate endoplasmic reticulum stress and suppress hepatocellular carcinoma in a chemically induced transgenic mouse model","volume":"12","author":"M\u00e1t\u00e9s","year":"2013","journal-title":"Lipids Health Dis"},{"key":"25","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1002\/cncr.25257","article-title":"Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma","volume":"116","author":"Cheng","year":"2010","journal-title":"Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000111709","article-title":"Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma","volume":"72","author":"Poon","year":"2007","journal-title":"Oncology"},{"key":"27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/02841860600702076","article-title":"Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma","volume":"46","author":"Goh","year":"2007","journal-title":"Acta Oncol"},{"key":"28","first-page":"861","article-title":"Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial","volume":"26","author":"Chen","year":"2007","journal-title":"Chin J Cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000074477","article-title":"Low-dose thalidomide treatment for advanced hepatocellular carcinoma","volume":"65","author":"Cheng","year":"2003","journal-title":"Oncology"},{"key":"30","unstructured":"Weisheng, Qiang, Yunbin, Hailan, Mingzhi, Wenchang, Kongzhi, Qizhong. Influence of treatment of HCC with thalidomide in combination with TACE on Quality of life. CHINESE JOURNAL OF CLINICAL ONCOLOGY AND REHABILITATION. 2007; pp. 478\u201380."},{"key":"31","unstructured":"Hai-lan. Yun-bin HM-zZW-sY, Jian-xiong CQ-zCJ-bZ. The changes of vascular endothelial growth factor after treatment of thalidomide combined with TACE for HCC. Zhongguo Jieru Yingxiang Yu Zhiliaoxue. 2007; pp. 440\u201343."},{"key":"32","first-page":"861","article-title":"[Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial] [Article in Chinese]","volume":"26","author":"Chen","year":"2007","journal-title":"Ai Zheng"},{"key":"33","unstructured":"Xiao-jun, Yu-dong. Treatment of primary hepatic cancer by transcatheter hepatic artery chemoembolization therapy combined with thalidomide. Chinese Journal Of Cancer Prevention And Treatment. 2007; pp. 788\u20139."},{"key":"34","first-page":"546","article-title":"Efficacy of combined thalidomide and interventional therapy in treatment of advanced hepatocellular carcinoma","volume":"50","author":"Jian-yu","year":"2007","journal-title":"Chinese Journal of Clinical Oncology And Rehabilitation"},{"key":"35","first-page":"29","article-title":"The Preliminary Observation of the Therapeutic Effect of Transcather Arterial Chemoembolization Combined with Thalidomide on Advanced Hepatic Carcinoma","volume":"4","author":"Chun-ying","year":"2008","journal-title":"PRACTICAL CLINICAL MEDICINE"},{"key":"36","unstructured":"Chang-nan, Qi-zuo, Yun-xiao, Ming-jun, Huo-xun, Jia-kang, Miao-wen, Jin-song. Effect of thalidomide combined with TACE on recurrence and survival of primary liver cancer. China Trop Med. 2008; pp. 406\u201308."},{"key":"37","unstructured":"Cheng, Changnan, Yunxiao, Mingjun, Zhijian, Qizuo, Bingzhao, Chanjuan, Tingjie, Feng. Clinical effect of transcatheter arterial chemoembolization combined with gimeracil and oteracil potassium and thalidomide in treatment of advanced hepatocellular carcinoma. Journal of Modern Oncology. 2015; pp. 2475\u20138."},{"key":"38","unstructured":"Xiao-bing, Xing-long, Xiang, Shi-wu, Cheng-fa, Man. Clinical research on advanced primary carcinoma of liver treated with transcatheter arterial chemoembolization combined Thalidomide. Anhui Medical and Pharmaceutical Journal. 2009; pp. 1270\u20132."},{"key":"39","unstructured":"Wei-min, Shi-wu, Xiang, Cheng-fa, Ma, Xiao-bing, Meng-qin, Rong-jie, Ying-xing. Clinical research on middle - high dose Thalidomide Combined TACE treatment of primary liver cancer. Anhui Medical Journal. 2009; pp. 1419\u201322."},{"key":"40","unstructured":"Yun-xiao, Chan-nan, Qi-zuo, Huo-xun. The Combination of Thalidomide with Transcatheter Arterial Chemoembolization in Treating Primary Liver Cancer. Journal of Gannan Medical University. 2010; pp. 44\u20135."},{"key":"41","unstructured":"Zenghu, Xiufang, Ruiliang, Quanfu. Clinical study of TACE combined with thalidomide and traditional Chinese medicine in patients with intermediate or advanced HCC. Journal of Emergency in Traditional Chinese Medicine. 2010; pp. 1492\u20133."},{"key":"42","unstructured":"Haiying, Xiaodong, Mei. The Analyses of Efficacy of Thalidomide Combined with Transcatheter Arterial Chemoembolization of Advanced Hepatocellular Carcinoma. JOURNAL OF BASIC AND CLINICAL ONCOLOGY. 2010; pp. 226\u20138."},{"key":"43","unstructured":"Fei. Therapeutic effect of thalidomide plus TACE for patients with intermediate or advanced primary hepatocellular carcinoma. Guide of China medicine. 2010; pp. 228\u20139."},{"key":"44","first-page":"871","article-title":"Combination of thalidomide and transcatheter arterial chemoembolization for advanced hepatocellular carcinoma","volume":"81","author":"Mei","year":"2011","journal-title":"China J Cancer Prev Treat"},{"key":"45","unstructured":"Yan, CM-cJ, Xue-ming, Shu-xun. Clinical study of transcatheter arterial chemoembolization combined with thalidomide on advanced hepatic carcinoma. Chinese Journal of Cancer Prevention and Treatment. 2011; pp. 1043\u20135."},{"key":"46","unstructured":"Jiqun, Bai, Bingshan, Xiaomei, Zhijian. Efficacy of the regimen of transcatheter arterial chemoembolization sequential thalidomide in advanced hepatocellular carcinoma. Journal of Modern Oncology. 2013; pp. 811\u20133."},{"key":"47","unstructured":"Zhenkai, Yaozhen, Yan. Effect of advanced hepatocellular carcinoma treated by conformal radiotherapy after thalidomide combined with trancather arterial chemoembolization. Journal of Modern Oncology. 2013; pp. 2276\u20139."},{"key":"48","unstructured":"Xia, Guangping, Jiqun. Effect of thalidomide combined with TACE on T lymphocytes and erythrocyte immune function of primary liver cancer. Shandong Yiyao. 2015; pp. 70\u201372."},{"key":"49","unstructured":"Xd, Dr. Huang Xz. Clinical observation of efficacy of thalidomide combined with TACE for patients with intermediate or advanced stage primary hepatocellular carcinoma. Jiangsu Med J. 2014; pp. 95\u20136."},{"key":"50","unstructured":"Kang, Mengguo, Zhixiang. Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis. J Clin Hepatol. 2016; pp. 899\u2013903."},{"key":"51","unstructured":"Xie, Zhang, Zhang, Xie, Yin, Xue, Chen, Wang, Zhang, Ren. Randomized controlled trial of thalidomide combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an interim analysis. National Liver Cancer Conference. 2015; p. 71."},{"key":"52","unstructured":"Weisheng, Qiang, Yunbin, Hailan, Mingzhi, Wenchang, Kongzhi, Qizhong. The Changes of Cellular Immunity Function After Treatment of Thalidomide Combined with TACE for HCC. JOURNAL OF BASIC AND CLINICAL ONCOLOGY. 2007; pp. 145\u20137."},{"key":"53","unstructured":"Yun-xiao, Chan-nan, Qi-zuo, Huo-xun. The Combination of Thalidomide with Transcatheter Arterial Chemoembolization in Treating Primary Liver Cancer. JOURNAL OF GANNAN MEDICAL UNIVERSITY. 2009; pp. 176\u20137."},{"key":"54","unstructured":"Hailan, Zhenhua, Mingzhi, Qiang, Hui, Wenchang, Kongzhi, Qizhong. The impact of thalidomide on the disease progression time after TACE in patients with primary heaptocellular carcinoma. Fujian Med J. 2007; pp. 14\u201316."},{"key":"55","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.leukres.2014.06.009","article-title":"Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials","volume":"38","author":"Hou","year":"2014","journal-title":"Leuk Res"},{"key":"56","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjh.12946","article-title":"Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis","volume":"166","author":"Avigdor","year":"2014","journal-title":"Br J Haematol"},{"key":"57","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3109\/10428194.2013.838232","article-title":"Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials","volume":"55","author":"Zhang","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2012.067058","article-title":"Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials","volume":"98","author":"P\u00e9gouri\u00e9","year":"2013","journal-title":"Haematologica"},{"key":"59","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2012.04.001","article-title":"Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis","volume":"36","author":"Kurokawa","year":"2012","journal-title":"Leuk Res"},{"key":"60","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hon.1025","article-title":"Postrelapse survival rate correlates with first-line treatment strategy with thalidomide in patients with newly diagnosed multiple myeloma: a meta-analysis","volume":"30","author":"Sheng","year":"2012","journal-title":"Hematol Oncol"},{"key":"61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Owen","year":"2012","journal-title":"Blood"},{"key":"62","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/00001813-200011000-00002","article-title":"Thalidomide in the treatment of cancer","volume":"11","author":"Adlard","year":"2000","journal-title":"Anticancer Drugs"},{"key":"63","doi-asserted-by":"crossref","first-page":"e91124","DOI":"10.1371\/journal.pone.0091124","article-title":"Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis","volume":"9","author":"Han","year":"2014","journal-title":"PLoS One"},{"key":"64","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00432-014-1684-5","article-title":"Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"140","author":"Liang","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"65","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1007\/s11033-014-3541-7","article-title":"Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"41","author":"Han","year":"2014","journal-title":"Mol Biol Rep"},{"key":"66","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1155\/2007\/128792","article-title":"Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy","volume":"21","author":"Bain","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"67","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2036.2005.02547.x","article-title":"alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma","volume":"22","author":"Whang-Peng","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"68","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic Landscape and Biomarkers of Hepatocellular Carcinoma","volume":"149","author":"Llovet","year":"2015","journal-title":"Gastroenterology"},{"key":"69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1148\/rg.352140119","article-title":"Anti-VEGF molecular targeted therapies in common solid malignancies: comprehensive update for radiologists","volume":"35","author":"Ramaiya","year":"2015","journal-title":"Radiographics"},{"key":"70","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.12659\/MSM.894617","article-title":"Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis","volume":"21","author":"Li","year":"2015","journal-title":"Med Sci Monit"},{"key":"71","first-page":"2205","article-title":"VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy","volume":"35","author":"Sumino","year":"2015","journal-title":"Anticancer Res"},{"key":"72","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000367739","article-title":"Surgical and Locoregional Therapy of HCC: TACE","volume":"4","author":"Murakami","year":"2015","journal-title":"Liver Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T15:02:23Z","timestamp":1596726143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,29]]},"references-count":72,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2017,7,4]]}},"alternative-id":["16689","28402958"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16689","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,29]]}}}